About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

CEDUR - German IBD Registry | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT07319442

CEDUR - German IBD Registry

The CEDUR registry systematically collects real-world data on inflammatory bowel disease (IBD) patients in Germany. The registry aims to assess quality of care, disease activity, treatment effectivene...

Lead sponsor: ImmunoRegister gUG•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Stefanie Howaldt, MD

CONTACT

+4940423265150 [email protected]

Sponsors

Lead Sponsor

ImmunoRegister gUG

CEDUR is a multicenter, web-based, observational registry for adult IBD patients in Germany. The registry includes Crohn's disease, ulcerative colitis, and indeterminate colitis. Data are collected prospectively from physicians and patients, covering clinical parameters, quality of life, treatment patterns, and safety outcomes. The registry supports the evaluation of care quality, cost-effectiveness, and long-term therapy outcomes under real-life conditions.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Crohn Disease Ulcerative Colitis Indterminate Colitis

Exclusion Criteria

•Other gastrointestinal disorders than above

Related studies

RECRUITINGPhase 4

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

NCT07292012 · Crohn Disease (CD)

RECRUITINGPhase 1/2

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

NCT07374471 · Ulcerative Colitis (UC)

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

NCT07271069 · Ulcerative Colitis (UC)

Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis

NCT07442045 · Ulcerative Colitis (UC)

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394 · Inflammatory Bowel Disease (IBD), Crohn Disease (CD), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 6, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment10,000

Start dateMay 2018

Last updatedJan 6, 2026

Condition

Ulcerative Colitis (UC)Indeterminate Colitis Crohn Disease (CD)

Locations shown

ImmunoRegister gUG

Hamburg

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 6, 2026Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions